Article Versions Notes

Daud ANA, Bergman JEH, Kerstjens-Frederikse WS, Groen H, Wilffert B. The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key? International Journal of Molecular Sciences. 2016; 17(8):1333. https://doi.org/10.3390/ijms17081333

Daud, Aizati N. A., Jorieke E. H. Bergman, Wilhelmina S. Kerstjens-Frederikse, Henk Groen, and Bob Wilffert. 2016. "The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key?" International Journal of Molecular Sciences 17, no. 8: 1333. https://doi.org/10.3390/ijms17081333

Daud, A. N. A., Bergman, J. E. H., Kerstjens-Frederikse, W. S., Groen, H., & Wilffert, B. (2016). The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key? International Journal of Molecular Sciences, 17(8), 1333. https://doi.org/10.3390/ijms17081333